Egrifta and “Unsound Medical Practice”
This article was originally published in RPM Report
Executive Summary
Contrary to popular belief, FDA did approve one weight loss therapy in 2010—TheraTechnologies Egrifta for treatment of lipodystropy associated with HIV medicines. Here is how FDA Division of Metabolic and Endocrinologic Drug Products Mary Park summarized the agency’s decision to approve an application for a narrow indication with very broad potential for inappropriate off-label use.